Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

BOULDER andNEW YORK CITY -- Array BioPharma (Nasdaq: ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) announced the companies have entered into a clinical research collaboration to investigate... Read More

Thursday June 1, 2017 0 comments Tags: Boulder, Array BioPharma, Bristol-Myers Squibb, Ron Squarer, Fouad Namouni

Array BioPharma announces strategic collaboration with Merck

Array BioPharma announces strategic collaboration with Merck

BOULDER -- Array BioPharma Inc .(Nasdaq: ARRY) announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outsidethe United StatesandCanada) to investigate... Read More

Tuesday May 9, 2017 0 comments Tags: Boulder, Array BioPharma, Merck, Ron Squarer, binimetinib, KEYTRUDA

Array BioPharma closes on stock sale raising $132.25M

Array BioPharma closes on stock sale raising $132.25M

BOULDER -- Array BioPharma Inc . (NasdaqGM: ARRY) today announced the closing of its underwritten public offering of 21,160,000 shares of its common stock, which includes 2,760,000 shares of... Read More

Wednesday October 5, 2016 0 comments Tags: Boulder, Array BioPharma

Array BioPharma selling 18.4M shares of stock to raise $115M to fund R&D

Array BioPharma selling 18.4M shares of stock to raise $115M to fund R&D

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the pricing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $6.25per... Read More

Wednesday September 28, 2016 0 comments Tags: Boulder, Array BioPharma

Array BioPharma, Pierre Fabre announce positive results for cancer drug

Array BioPharma, Pierre Fabre announce positive results for cancer drug

BOULDER -- Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS ( Co mbined L GX818 U sed with M EK162 in B RAF... Read More

Monday September 26, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Keith T. Flaherty, encorafenib, binimetinib, Frederic Duchecesne, COLUMBUS

Array BioPharma: FDA accepts New Drug Application for melanoma

Array BioPharma: FDA accepts New Drug Application for melanoma

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act... Read More

Thursday September 1, 2016 0 comments Tags: Boulder, Array BioPharma, binimetinib, Dr. Victor Sandor

Array BioPharma appoints Jason Haddock CFO

Array BioPharma appoints Jason Haddock CFO

BOULDER -- Array BioPharma (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted... Read More

Thursday July 28, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Jason Haddock, David Horin

Array BioPharma submits New Drug Application for binimetinib to FDA

Array BioPharma submits New Drug Application for binimetinib to FDA

BOULDER -- Array BioPharma (Nasdaq:ARRY) announced it submitted a New Drug Application (NDA) to the FDA for binimetinib in patients with advanced NRAS -mutant melanoma. The submission is... Read More

Friday July 1, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib